Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Ecora Royalties PLC (ECOR:CA) Q4 2025 Earnings Call Transcript

electroCore, Inc. (ECOR) Q4 2025 Earnings Call Transcript

electroCore, Inc. (ECOR) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to a loss of $0.4 per share a year ago.

Record f ull year 2025 net sales of $ 32.0 , an increase of 27% over $25.2 million for the full year 2024 driven by 25% annual growth in our U.S. prescription business and 97% increase in general wellness sales

ROCKAWAY, N.J., March 10, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a bioelectronic medicine and wellness company, announced today that management will participate in the 38th Annual Roth Conference March 22-24 at the Ritz-Carlton in Laguna Niguel, California.

ROCKAWAY, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report financial results for the fourth quarter and full year ended December 31, 2025, after the close of the market on Thursday, March 19, 2026.

electroCore (ECOR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.